BIOS: BioScrip, Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 21, 10:01 AM Jefferies initiates BioScrip (BIOS +3%) at Buy with a $17 price target citing expectations "for sustained, robust top line and EBITDA growth over the next five years" and the likelihood of "incremental market share gains." On the latest CC, management told analyst Brian Tanquilut that the reduced interest expense from a debt refinancing would more than offset the increase in aggregate principal necessary to pay the associated redemption premium. (transcript) Comment! [On the Move, Healthcare]
Wednesday, May 8, 5:41 PM Bioscrip (BIOS): FQ4 EPS of $0.04 beats by $0.02. Revenue of $199.1M beats by $9.74M. (PR) Comment! [Earnings, Breaking News]
Wednesday, April 17, 2:12 PM BioScrip (BIOS -6.3%) slides today after announcing a $75M stock offering, while affiliates of its largest shareholders offer an additional $25M. BIOS won't receive any proceeds from the shareholders' portion of the sale. Jefferies, Morgan Stanley and SunTrust Robinson Humphrey are acting as joint book-running managers. Additionally, the company says it intends to refinance its existing indebtedness with the proceeds of a new $325M senior secured credit facility, including a revolving credit facility and a term loan. Comment! [Healthcare, On the Move]
Monday, March 11, 5:55 PM More on BioScrip (BIOS): Q4 easily beats across the board on a 14% rise in total sales. Gross profit from continuing operations was 33.4% of revenue, as compared to 37.0% in the prior year period. For FY13, the company sees revenues in a range of $830M to $865M and is initially targeting 2013 Adjusted EBITDA of $67M to $73M. Analysts are forecasting revenues of $769.9M and EBITDA of $67.8M. Shares +8.3% AH. Comment! [Healthcare, Earnings, On the Move]
Monday, March 11, 4:52 PM Bioscrip (BIOS): Q4 EPS of $0.04 beats by $0.03. Revenue of $180.7M (+14.2% Y/Y) beats by $6.83M. Shares +4.7% AH. (PR) Comment! [Earnings, Breaking News, On the Move]
Thursday, December 13, 2012, 12:46 PM BioScrip (BIOS +1.7%) moves up after announcing earlier today that it was buying infusion pharmacy services provider HomeChoice Partners for $70M in cash from DaVita HealthCare Partners (DVA -0.3%). The deal is part of a larger effort by BIOS to expand its national footprint. In February, it sold its specialty and mail-service pharmacy operations to Walgreen (WAG)for $225M, saying it wanted to turn its focus onto building its alternate-site infusion business. Comment! [Healthcare, M&A, On the Move]
Wednesday, November 7, 2012, 5:44 PM BioScrip (BIOS): Q3 EPS of -$0.01 beats by $0.01. Revenue of $170.4M (+27.3% Y/Y) beats by $10M. (PR) Comment! [Earnings]
Wednesday, August 8, 2012, 4:58 PM BioScrip (BIOS): Q2 EPS of -$0.07 misses by $0.06. Revenue of $155.9M (+18.2% Y/Y) beats by $2M. (PR) 1 Comment [Earnings]
Wednesday, May 9, 2012, 7:08 AM BioScrip (BIOS): Q1 EPS of -$0.05 may not be comparable to consensus of $-0.01. Revenue of $155.6M (+19% Y/Y) beats by $12M. (PR) Comment! [Earnings]
Friday, March 9, 2012, 7:09 AM BioScrip (BIOS): Q4 EPS of $0.12 beats by $0.03. Revenue of $483.3M (+7.3% Y/Y) beats by $24M. (PR) Comment! [Earnings]
Thursday, February 2, 2012, 8:13 AM More on the WAG-BIOS deal (previous): BioScrip (BIOS) will come out of the deal considerably leaner, but will still have its infusion, home health, pharmacy benefit management and cash card businesses. The firm also say that it will continue to service its infusion patient base and managed care customers through its pharmacies. Shares of BIOS are currently halted. Comment! [M&A]
Thursday, February 2, 2012, 8:09 AM Walgreen (WAG) snaps up assets of BioScrip (BIOS) including community specialty pharmacies and centralized specialty and mail service pharmacy businesses for a total deal value of $225M. The agreement calls for an additional $60M payment depending on if Walgreen retains some of the lines of business. Shares of WAG -0.3% premarket, BIOS halted. Comment! [M&A]
Wednesday, September 28, 2011, 2:03 PM Shares of BioScrip (BIOS) gain 7% after BB&T initiates with a Buy rating and an elevated price target of $10 - repping 61% upside potential for shares of the pharmacy and home health provider. Comment! [On the Move, Healthcare]

BIOS BioScrip, Inc.

BIOS

BioScrip, Inc.